DESIGN THERAPEUTICS INC's ticker is DSGN and the CUSIP is 25056L103. A total of 97 filers reported holding DESIGN THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 19.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,721,575 | -15.7% | 2,304,948 | +1.4% | 0.00% | – |
| Q1 2024 | $9,164,989 | +45.3% | 2,274,191 | -4.5% | 0.00% | – |
| Q4 2023 | $6,307,642 | +11.2% | 2,380,242 | -1.0% | 0.00% | – |
| Q3 2023 | $5,673,240 | -69.9% | 2,403,915 | -19.7% | 0.00% | -100.0% |
| Q2 2023 | $18,862,523 | +2.6% | 2,994,051 | -6.0% | 0.00% | 0.0% |
| Q1 2023 | $18,382,592 | -48.9% | 3,185,891 | -9.2% | 0.00% | 0.0% |
| Q4 2022 | $35,992,328 | -40.2% | 3,508,024 | -2.5% | 0.00% | -50.0% |
| Q3 2022 | $60,177,000 | +21.4% | 3,599,125 | +1.7% | 0.00% | 0.0% |
| Q2 2022 | $49,559,000 | -2.6% | 3,539,936 | +12.3% | 0.00% | +100.0% |
| Q1 2022 | $50,887,000 | +7.3% | 3,150,820 | +42.2% | 0.00% | 0.0% |
| Q4 2021 | $47,438,000 | +146.0% | 2,215,624 | +68.8% | 0.00% | 0.0% |
| Q3 2021 | $19,282,000 | -30.9% | 1,312,664 | -6.5% | 0.00% | 0.0% |
| Q2 2021 | $27,911,000 | +18.0% | 1,403,342 | +77.4% | 0.00% | 0.0% |
| Q1 2021 | $23,652,000 | – | 791,019 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 6,526,476 | $21,863,695 | 6.84% |
| Almitas Capital LLC | 1,253,248 | $4,198,381 | 1.75% |
| Logos Global Management LP | 5,032,501 | $16,858,878 | 1.37% |
| BML Capital Management, LLC | 421,749 | $1,412,859 | 1.01% |
| TANG CAPITAL MANAGEMENT LLC | 1,480,975 | $4,961,266 | 0.50% |
| Frazier Life Sciences Management, L.P. | 1,195,179 | $4,003,850 | 0.19% |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 343,000 | $1,149,000 | 0.18% |
| Opaleye Management Inc. | 205,000 | $686,750 | 0.16% |
| Baker Brothers Advisors | 1,695,294 | $5,679,235 | 0.07% |
| GSA CAPITAL PARTNERS LLP | 209,953 | $703 | 0.05% |